IBJNews

BioCrossroads seeds upstart medical device maker

Back to TopCommentsE-mailPrintBookmark and Share

BioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company developing an absorbable stent to treat cardiovascular disease.

Zorion Medical is chaired by former Eli Lilly and Co. executive David Broecker, who has relocated to Indianapolis from Boston. Broecker, a Wabash College graduate in chemistry and mathematics, previously was president and CEO of Cambridge, Mass.-based biopharmaceutical company Alkermes Inc.

Broecker also is CEO of BioCritica Inc., a locally-based firm founded last May that acquired commercialization rights to Lilly’s Xigris, a drug to treat the blood infection sepsis.

The BioCrossroads investment in Zorion will help fund further proof-of-concept work, including another pre-clinical study Zorion plans in the first quarter of 2012 involving animals.

The company developed a stent that can be absorbed into the body—essentially to disappear.

The biomaterial also can deliver drugs to help heal the artery.

Stents—mesh-like tubes—are implanted to prop open narrowed arteries. Traditionally they’ve been made from metal and designed to be a permanent fixture in the artery. The downside is that clotting may occur, requiring patients to take blood thinners.

Medical device companies have been developing stents that can be absorbed into an artery. Most of these, including one recently launched by Abbott Laboratories, are made of a polymer material and take up to two years to disappear in the body.

Zorion’s stent is made of a metal-like substance that is said to disappear in only three to six months. Broecker has likened Zorion’s product to a splint rather than a stent.

Another potential market advantage of Zorion’s metallic-based absorbable material is that cardiologists are already familiar with the properties of metal stents.

“We hope to be a fast follower” to polymer stents, said Broecker.

“Fast” is relative in the highly regulated medical device industry. Broecker said a market launch in five years is probably a safe bet. A partnership with an established player in the cardiology market is a possibility.

In the meantime, the upstart has been operating much as a virtual company, with its handful of employees scattered as far as Europe.

Broecker said he is hopeful of building jobs in the Indianapolis area as stent development and testing progresses.

Metal and drug-eluting stents are a $6 billion market globally.

“It’s obviously an enormous market and this is very disruptive technology,” said David Johnson, president and CEO of BioCrossroads, saying Zorion’s approach has the potential to be a “tremendous breakthrough technology.”

The $6 million Indiana Seed Fund was launched in 2005.  Zorion represents its 12th investment.

Periculum Capital, an Indianapolis-based private investment and merchant banking group, also made an undisclosed investment in Zorion, Biocrossroads said.

BioCrossroads is the state's initiative to grow the life sciences industry.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT